6J98
 
 | |
7YSI
 | | Crystal structure of thioredoxin 2 | | Descriptor: | Thiol disulfide reductase thioredoxin, ZINC ION | | Authors: | Chang, Y.J, Park, H.H. | | Deposit date: | 2022-08-12 | | Release date: | 2023-03-15 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (1.202 Å) | | Cite: | Comparison of the structure and activity of thioredoxin 2 and thioredoxin 1 from Acinetobacter baumannii.
Iucrj, 10, 2023
|
|
7XAO
 | | Crystal structure of thioredoxin 1 | | Descriptor: | Thioredoxin | | Authors: | Chang, Y.J, Park, H.H. | | Deposit date: | 2022-03-18 | | Release date: | 2022-06-01 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (1.45 Å) | | Cite: | High-resolution crystal structure of Acinetobacter baumannii thioredoxin 1.
Biochem.Biophys.Res.Commun., 608, 2022
|
|
1WKQ
 | |
4UIP
 | | The complex structure of extracellular domain of EGFR with Repebody (rAC1). | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, EPIDERMAL GROWTH FACTOR RECEPTOR, ... | | Authors: | Kang, Y.J, Cha, Y.J, Cho, H.S, Lee, J.J, Kim, H.S. | | Deposit date: | 2015-03-31 | | Release date: | 2015-11-25 | | Last modified: | 2024-01-10 | | Method: | X-RAY DIFFRACTION (2.95 Å) | | Cite: | Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein-Drug Conjugates for Targeted Therapy.
Angew.Chem.Int.Ed.Engl., 54, 2015
|
|
4CQG
 | | The crystal structure of MPK38 in complex with OTSSP167, an orally- administrative MELK selective inhibitor | | Descriptor: | 1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-({trans-4-[(dimethylamino)methyl]cyclohexyl}amino)-1,5-naphthyridin-3-yl]ethanone, Maternal embryonic leucine zipper kinase, SULFATE ION | | Authors: | Cho, Y.S, Kang, Y.J, Cho, H.S. | | Deposit date: | 2014-02-17 | | Release date: | 2014-07-09 | | Last modified: | 2023-12-20 | | Method: | X-RAY DIFFRACTION (2.57 Å) | | Cite: | The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.
Biochem.Biophys.Res.Commun., 447, 2014
|
|
7FDJ
 | | Engineered Hepatitis B virus core antigen with short linker T=4 | | Descriptor: | Capsid protein,Immunoglobulin G-binding protein A | | Authors: | Jeong, H, Heo, Y, Yoo, Y, Ryu, B, Yun, J, Cho, H, Lee, W. | | Deposit date: | 2021-07-16 | | Release date: | 2021-09-01 | | Last modified: | 2024-06-12 | | Method: | ELECTRON MICROSCOPY (4.4 Å) | | Cite: | Structural and Functional Characterizations of Cancer Targeting Nanoparticles Based on Hepatitis B Virus Capsid.
Int J Mol Sci, 22, 2021
|
|
7EP6
 | | Engineered Hepatitis B virus core antigen T=4 | | Descriptor: | Capsid protein,Immunoglobulin G-binding protein A | | Authors: | Jeong, H, Heo, Y, Yoo, Y, Ryu, B, Yun, J, Cho, H, Lee, W. | | Deposit date: | 2021-04-26 | | Release date: | 2021-09-01 | | Last modified: | 2022-02-16 | | Method: | ELECTRON MICROSCOPY (3.86 Å) | | Cite: | Structural and Functional Characterizations of Cancer Targeting Nanoparticles Based on Hepatitis B Virus Capsid.
Int J Mol Sci, 22, 2021
|
|
7EOY
 | | Engineered Hepatitis B virus core antigen T=3 | | Descriptor: | Capsid protein,Immunoglobulin G-binding protein A | | Authors: | Jeong, H, Heo, Y, Yoo, Y, Ryu, B, Yun, J, Cho, H, Lee, W. | | Deposit date: | 2021-04-24 | | Release date: | 2021-09-01 | | Last modified: | 2022-02-16 | | Method: | ELECTRON MICROSCOPY (3.6 Å) | | Cite: | Structural and Functional Characterizations of Cancer Targeting Nanoparticles Based on Hepatitis B Virus Capsid.
Int J Mol Sci, 22, 2021
|
|
2GQG
 | | X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain | | Descriptor: | GLYCEROL, N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE, Proto-oncogene tyrosine-protein kinase ABL1 | | Authors: | Klei, H.E. | | Deposit date: | 2006-04-20 | | Release date: | 2006-11-21 | | Last modified: | 2017-10-18 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants
CANCER RES., 66, 2006
|
|
